Management of osteoporosis in children.
Osteoporosis is being increasingly recognised in paediatric practice as a consequence of several factors. These include the increasing complexity of chronic conditions and the associated treatments managed by paediatricians. In addition, the improved care provided to children with chronic illness has led to many of them living long enough to develop osteoporosis. The availability of methods to assess bone density in children as a surrogate marker of bone strength and the possibility of medical treatment to increase bone density have also resulted in an increased awareness of groups of children who may be at risk of osteoporosis. This article reviews the current definition of osteoporosis in children, aetiological factors and the evidence for effective treatment.
Shaw
Nicholas J
NJ
Department of Endocrinology, Birmingham Children's Hospital, Steelhouse Lane, Birmingham B46NH, UK. nick.shaw@bch.nhs.uk
D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D001842:Bone and Bones / Q000002:abnormalities; D002648:Child; D016207:Cytokines / Q000378:metabolism; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D051346:Mobility Limitation; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D011322:Primary Prevention / Q000379:methods; D011628:Puberty, Delayed / Q000150:complications; D009626:Terminology as Topic; D013851:Thinness / Q000150:complications
D050071:Bone Density Conservation Agents; D016207:Cytokines; D004164:Diphosphonates; D005938:Glucocorticoids; D018836:Inflammation Mediators